This Cancer Drug Candidate Could Be a Hit for Pfizer

Late last month, the U.S. Food and Drug Administration (FDA) granted priority review to Pfizer’s (NYSE: PFE) multiple myeloma (MM) drug candidate elranatamab. With a decision from the FDA expected sometime this year, the investigational therapy could be approved quite soon.